{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-24-000078","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.645100+00:00","generated_at":"2026-05-30T01:01:32.487295+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immuneering Q3 net loss $14.6M; positive initial Phase 2a data for IMM-1-104","bullets":["Net loss $14.6M ($0.49/share) vs $12.6M ($0.43) in Q3 2023; cash $50.7M.","Positive initial Phase 2a data: complete and partial responses with IMM-1-104 + chemo in first-line pancreatic cancer.","FDA granted Orphan Drug and Fast Track designations for IMM-1-104 in pancreatic cancer.","Cash runway into Q4 2025; R&D expenses $11.3M, G&A $4.0M.","Initial data from additional Phase 2a arm and Phase 1 data for IMM-6-415 expected by year end."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-24-000078","json":"https://secwatch.observer/filing/0001790340-24-000078.json","markdown":"https://secwatch.observer/filing/0001790340-24-000078.md","text":"https://secwatch.observer/filing/0001790340-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/0001790340-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/imrx-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:01:32.487295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}